SCHEMBL1528149

SCHEMBL1528149

CCCCc1nc2c(N)nc3ccccc3c2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 19/20 1.00
TLR7 Q9NYK1 17/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1527936 0.96 TLR8 (1.00) TLR8TLR7
SCHEMBL29373816 0.92 TLR8 (1.00) TLR8TLR7
SCHEMBL482958 0.92 TLR8 (1.00) TLR8TLR7
Hydrochloric Acid SCHEMBL5765916 0.90 TLR8 (0.97) TLR8TLR7
SCHEMBL1528137 0.86 TLR8 (1.00) TLR8TLR7
Hydrochloric Acid SCHEMBL5767005 0.85 TLR8 (0.97) TLR8TLR7
SCHEMBL1527831 0.83 TLR8 (0.75) TLR8TLR7
SCHEMBL1528010 0.82 TLR8 (0.69) TLR8TLR7
SCHEMBL1528044 0.80 TLR8 (0.74) TLR8TLR7
SCHEMBL1528088 0.80 TLR8 (0.73) TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4662630-B2 2011-03-30 JP claimed
US-6894060-B2 Method for the treatment of dermal lesions caused by envenomation 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-05-17 US claimed
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US claimed
US-20030195224-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-10-16 US claimed
EP-1100802-B1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2003-09-24 EP claimed
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US claimed
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US claimed
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-03-06 US claimed
JP-2002524392-A 2002-08-06 JP claimed
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2002-06-13 US claimed
US-20020016332-A1 Imidazo-, oxazolo- and thiazolo- pyridineamines and naphthyridineamines which may be fused to cycloalkyl or benzene rings as immune reponse modifiers 3M INNOVATIVE PROPERTIES COMPANY 2002-02-07 US claimed
WO-2001074343-A2 METHOD FOR THE TREATMENT OF DERMAL LESIONS CAUSED BY ENVENOMATION 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-10-11 WO claimed
EP-1100802-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2001-05-23 EP claimed
US-6110929-A IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-29 US claimed
WO-2000006577-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-02-10 WO claimed
US-7485432-B2 Selective modulation of TLR-mediated biological activity 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-02-03 US disclosed
EP-1755665-A2 COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION 3M Innovative Properties Company (US) 2007-02-28 EP disclosed
EP-1100802-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2001-05-23 EP disclosed
US-6110929-A IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-29 US disclosed
WO-2000006577-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 TLR8 290/4885TLR7 109/4885
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 TLR8 290/4885TLR7 109/4885
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 TLR8 290/4885TLR7 109/4885
US-20030195224-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof IFNG, THPO, IL2 TLR8 290/4885TLR7 109/4885
US-20020016332-A1 Imidazo-, oxazolo- and thiazolo- pyridineamines and naphthyridineamines which may be fused to cycloalkyl or benzene rings as immune reponse modifiers STING1, HRH4, ICOS TLR8 89/4885TLR7 19/4885
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 TLR8 290/4885TLR7 109/4885
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 TLR8 290/4885TLR7 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.